4.6 Article

NKCC1 (SLC12a2) induces a secondary axis in Xenopus laevis embryos independently of its co-transporter function

Journal

JOURNAL OF PHYSIOLOGY-LONDON
Volume 587, Issue 3, Pages 521-529

Publisher

WILEY
DOI: 10.1113/jphysiol.2008.161562

Keywords

-

Funding

  1. Association for International Cancer Research

Ask authors/readers for more resources

NKCC1 is a broadly expressed Na+-K+-Cl- co-transporter involved in regulation of ion flux across the cell membrane and in regulating cell volume. Whilst much is known about the co-transporter activity of NKCC1 and its regulation by protein kinases and phosphatases, little is known about the activities of NKCC1 that are co-transporter independent. In this report we show that over-expression of NKCC1 in embryos of Xenopus laevis induces secondary axes, independently of its co-transporter activity. In addition, over-expression of NKCC1 results in the formation of neural tissue in ectodermal explants. We also show that NKCC1 is expressed broadly but non-uniformly in embryos of Xenopus laevis and Xenopus tropicalis, with prominent expression in the notochord, nervous system and stomach. These results provide insights into an additional, previously unreported activity of NKCCl.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Physiology

Liver Specification in the Absence of Cardiac Differentiation Revealed by Differential Sensitivity to Wnt/β Catenin Pathway Activation

Kim Hawortht, Lee Samuel, Sarah Black, Pavel Kirilenko, Branko Latinkic

FRONTIERS IN PHYSIOLOGY (2019)

Review Oncology

Epigenetic Targets in Synovial Sarcoma: A Mini-Review

Ryland Hale, Sami Sandakly, Janet Shipley, Zoe Walters

FRONTIERS IN ONCOLOGY (2019)

Article Hematology

The Long Noncoding RNA RP11-728F11.4 Promotes Atherosclerosis

Xian-Hui Dong, Zhi-Feng Lu, Chun-Min Kang, Xue-Heng Li, Kim E. Haworth, Xin Ma, Jing-Bo Lu, Xue-Hui Liu, Fu-Chun Fang, Claire S. Wang, John H. Ye, Lei Zheng, Qian Wang, Shu Ye, Yan-Wei Hu

Summary: RP11-728F11.4 plays a role in promoting atherosclerosis by influencing cholesterol homeostasis and proinflammatory molecule production, indicating its potential as a therapeutic target.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2021)

Article Oncology

Role for the Histone Demethylase KDM4B in Rhabdomyosarcoma via CDK6 and CCNA2: Compensation by KDM4A and Apoptotic Response of Targeting Both KDM4B and KDM4A

Zoe S. Walters, Ewa Aladowicz, Barbara Villarejo-Balcells, Gary Nugent, Joanna L. Selfe, Paul Eve, Julian Blagg, Olivia Rossanese, Janet Shipley

Summary: Rhabdomyosarcomas (RMS) are soft tissue sarcomas predominantly found in children, and current treatments have severe side effects and poor outcomes, necessitating the discovery of novel, more targeted therapies. High expression of histone demethylases, particularly KDM4B, supports proliferation of RMS cells, and sustained knockdown of KDM4B can lead to functional compensation by KDM4A. Targeting both KDM4A and KDM4B is shown to be effective in killing RMS cells and overcoming functional redundancy in order to elicit strong therapeutic responses.

CANCERS (2021)

Review Oncology

Histone Modifying Enzymes as Targets for Therapeutic Intervention in Oesophageal Adenocarcinoma

Oliver J. Pickering, Stella P. Breininger, Timothy J. Underwood, Zoe S. Walters

Summary: Despite advances in the treatment of oesophageal adenocarcinoma, the overall prognosis remains poor with few patients surviving more than 5 years from diagnosis. Epigenetic targets, specifically histone-modifying enzymes, have been identified as potential novel therapeutic options in OAC. Research on their roles in tumor formation and potential use as targeted therapies is ongoing.

CANCERS (2021)

Article Oncology

Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma

Fereshteh Izadi, Benjamin P. Sharpe, Stella P. Breininger, Maria Secrier, Jane Gibson, Robert C. Walker, Saqib Rahman, Ginny Devonshire, Megan A. Lloyd, Zoe S. Walters, Rebecca C. Fitzgerald, Matthew J. J. Rose-Zerilli, Tim J. Underwood

Summary: Esophageal adenocarcinoma (EAC) patients receive pre-operative chemotherapy, but a significant portion do not respond to this treatment, exhibiting chromosomal instability and gene copy number alterations. Different genetic profiles, including mutations in the tumor suppressor NAV3, are associated with non-responders, presenting potential drug targets for alternative treatment pathways.

CANCERS (2021)

Article Oncology

FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas

Christopher I. Milton, Joanna Selfe, Ewa Aladowicz, Stella Y. K. Man, Carolina Bernauer, Edoardo Missiaglia, Zoe S. Walters, Susanne A. Gatz, Anna Kelsey, Melanie Generali, Gary Box, Melanie Valenti, Alexis de Haven-Brandon, David Galiwango, Angela Hayes, Matthew Clarke, Elisa Izquierdo, David Gonzalez De Castro, Florence I. Raynaud, Vladimir Kirkin, Janet M. Shipley

Summary: High expression of FGFR2 and FGF7 in fusion-gene-positive rhabdomyosarcomas correlates with increased sensitivity of the cells and forms a novel autocrine loop mechanism. FGFR inhibitor NVP-BGJ398 reduces cell viability and shows synergistic effects with SN38.

MOLECULAR ONCOLOGY (2022)

Article Biochemistry & Molecular Biology

Pathogenic KDM5B variants in the context of developmental disorders

Jack Harrington, Gabrielle Wheway, Sandrine Willaime-Morawek, Jane Gibson, Zoe S. Walters

Summary: Histone modifying enzymes, especially KDM5B, play a critical role in development and developmental disorders. Understanding the mechanism of KDM5B can provide insights into development and developmental disorders.

BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2022)

Review Oncology

The genetic profile and molecular subtypes of human pseudomyxoma peritonei and appendiceal mucinous neoplasms: a systematic review

Nora Wangari Murage, Nada Mabrouk Ahmed, Timothy J. Underwood, Zoe S. Walters, Stella Panagio Breininger

Summary: Pseudomyxoma peritonei (PMP) is a rare neoplastic condition with a low survival rate. Understanding the genetic profile of PMP can help develop targeted treatments and predict patient survival.

CANCER AND METASTASIS REVIEWS (2023)

Review Oncology

Genomic and Epigenetic Changes Drive Aberrant Skeletal Muscle Differentiation in Rhabdomyosarcoma

Silvia Pomella, Sara G. Danielli, Rita Alaggio, Willemijn B. Breunis, Ebrahem Hamed, Joanna Selfe, Marco Wachtel, Zoe S. Walters, Beat W. Schaefer, Rossella Rota, Janet M. Shipley, Simone Hettmer

Summary: Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in children and adolescents, characterized by aberrant muscle differentiation. Abnormalities in the regulatory transcription factors (MRFs) involved in skeletal muscle development contribute to tumorigenesis in RMS. Core regulatory circuitries (CRCs) and hierarchically organized subsets of cells play a role in maintaining the disease-driving fusion oncogene and promoting malignancy in RMS. Understanding the genetic and epigenetic framework of abnormal muscle differentiation in RMS provides insights into its mechanisms and potential therapeutic strategies.

CANCERS (2023)

Article Oncology

Machine learning to predict curative multidisciplinary team treatment decisions in oesophageal cancer

Navamayooran Thavanesan, Indu Bodala, Zoe Walters, Sarvapali Ramchurn, Timothy J. Underwood, Ganesh Vigneswaran

Summary: This experimental pilot study developed machine learning models to predict treatment decisions in oesophageal cancer multidisciplinary teams. Results showed that multinomial logistic regression outperformed other algorithms in terms of performance metrics. Age was identified as a major factor in the decision-making process.
Article Oncology

Pharmacological EZH2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells

Eleanor O'Brien, Carmen Tse, Ian Tracy, Ian Reddin, Joanna Selfe, Jane Gibson, William Tapper, Reuben J. Pengelly, Jinhui Gao, Ewa Aladowicz, Gemma Petts, Khin Thway, Sergey Popov, Anna Kelsey, Timothy J. Underwood, Janet Shipley, Zoe S. Walters

Summary: This study demonstrates the potential utility of combining EZH2 inhibitors with differentiation agents for the treatment of paediatric rhabdomyosarcomas, providing a basis for further research and clinical application.

CLINICAL EPIGENETICS (2023)

Article Cell Biology

Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts

Benjamin P. Sharpe, Annette Hayden, Antigoni Manousopoulou, Andrew Cowie, Robert C. Walker, Jack Harrington, Fereshteh Izadi, Stella P. Breininger, Jane Gibson, Oliver Pickering, Eleanor Jaynes, Ewan Kyle, John H. Saunders, Simon L. Parsons, Alison A. Ritchie, Philip A. Clarke, Pamela Collier, Nigel P. Mongan, David O. Bates, Kiren Yacqub-Usman, Spiros D. Garbis, Zoe Walters, Matthew Rose-Zerilli, Anna M. Grabowska, Timothy J. Underwood

Summary: This study reveals that cancer-associated fibroblasts (CAFs) drive chemotherapy resistance in esophageal adenocarcinomas (EACs) and can be targeted with phosphodiesterase type 5 inhibitors (PDE5i) to enhance chemotherapy efficacy.

CELL REPORTS MEDICINE (2022)

Meeting Abstract Oncology

Digital Pathology and Machine Learning for Prediction of Response to Neoadjuvant Chemotherapy in Oesophageal Adenocarcinoma

B. Sharpe, S. Rahman, J. Early, G. Vigneswaran, J. Horne, B. Grace, J. West, Z. Walters, S. Ramchurn, T. Underwood

JOURNAL OF PATHOLOGY (2021)

No Data Available